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Available online xxxxBackground: Hypercholesterolemia is the accepted causal risk factor for atherosclerotic cardiovascular disease
(ASCVD). 2013 ACC/AHA guideline on the treatment of cholesterol advised to tailor high-intensity statin for pa-
tients with coronary artery disease (CAD). However, its impact of real clinical practice has not been examined in
China.
Methods: In this cross-sectional study, 3592 patients with CAD were consecutively enrolled who were receiving
statins in outpatient department (at least 4 weeks) before they were admitted to the ward at ﬁve University hospi-
tals from April 2011 to December 2015. Patients were divided into two groups according to the admission time be-
fore (group A, n= 1521) or after (group B, n= 2071) online announcement date of 2013 ACC/AHA guideline. The
situation of statin application and LDL-C target achievement (LDL-C b 1.8 mmol/L) in both groups were compared.
Results: Data indicated that the constituent ratio of different kinds of statins usage was signiﬁcantly different be-
tween the two groups (p b 0.05), and the proportion of rosuvastatin application grew up in group B (20.00%)
when compared with group A (10.50%, p b 0.05). However, the mean dosage of atorvastatin or rosuvastatin had
no signiﬁcant change. More importantly, the achievement of LDL-C target in both groups was still extremely low
(27.9% in group A vs. 26.9% in group B, p = 0.5077).
Conclusion: No much change of clinical practice with regard to cholesterol management was found in Chinese pa-
tients with CAD, accompanied by very low achievement of LDL-C target, suggesting that there is a great room for
the improvement of cholesterol control in Chinese patients with CAD.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cardiovascular diseases (CVDs) are the leading cause of death
worldwide [1]. Low-density lipoprotein cholesterol (LDL-C) is the ﬁrst
cause for atherosclerotic vascular disease (ASCVD). Undoubtedly,
numerous evidences from randomized clinical trials (RCTs) have been
demonstrated that cholesterol-lowering therapy can reduce themortal-
ity of ASCVD [2]. Statins are widely used and have been proven to beia, State Key Laboratory of
er for Cardiovascular Disease,
edical College, Beijing 100037,
is an open access article under the Ceffective in the prevention of ASCVD events, primarily by reducing
plasma LDL-C concentrations. Unfortunately, the incidence of ASCVD
is still increasing not only in developed countries, but also in the devel-
oping countries, especially in China, even in the era of statin [3–5].
The National Heart, Lung, and Blood Institute (NHLBI), in collabora-
tion with the American College of Cardiology (ACC) and the American
Heart Association (AHA), released the revised cholesterol management
guideline in 2013 [6]. The 2013 ACC/AHA guideline on the Treatment of
Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
represents a major shift from prior cholesterol management guideline.
The new guideline includes data from individual randomized trials as
well as the most comprehensive meta-analyses. The 2013 ACC/AHA
guideline emphasized the important meaning of cholesterol-lowering
therapy in primary and secondary prevention of ASCVD. Some newC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of statins according to their ability of lowering LDL-C. Statins were de-
ﬁned as high-intensity, moderate-intensity and low-intensity statins.
The guideline has a broader focus on risk of ASCVD including stroke,
and identify four statin beneﬁt patient groups that beneﬁt from either
“high-intensity” or “moderate-intensity” statin therapy rather than
LDL-C or non-HDL-C targets. The four major statin beneﬁt patient
groups include 1) individuals with clinical ASCVD; 2) primary eleva-
tions of LDL-C ≥ 190 mg/dL; 3) diabetics aged 40–75 years with LDL-C
70–189 mg/dL and without clinical ASCVD; and the guideline recom-
mended that high-intensity statins should be used in those patients
who are diagnosed as ASCVD with age 40–75, whatever the baseline
level of LDL-C. It is unknown that the impact of 2013ACC/AHAguideline
on the clinical practice of the cardiologists in real world in China.
In this study, therefore, we tried to investigate the impact of the
2013 ACC/AHA guideline on the statin prescriptions of cardiologists
for those patients with CAD using multiple center manner. At the
same time, we also analyzed the LDL-C target achievement between
the patients who took statins before the announcement of 2013 ACC/
AHA guideline and those patients who were prescribed statins after
the announcements of the guideline.
2. Methods
2.1. Study population
We enrolled consecutively 3592 patients with conﬁrmed diagnosis
of coronary artery disease (CAD) who were receiving statins in outpa-
tient department before they were admitted to theward at ﬁve Univer-
sity hospitals from April 2011 to December 2015. These patients were
divided into the two groups according to the admission time before
(group A, n=1521) or after (group B, n=2071) online announcement
date of 2013 ACC/AHA guideline. We analyzed the situation of different
kinds of statins application and the difference of average level of LDL-C
after treatment of statins between the two groups. We also made an
analysis about the change of the control rate of LDL-C b 1.8 mmol/L in
both groups. Including criteria: age 18–75 years old, males or females,
angiography-proven CAD, and taking statin every day for at least
4 weeks. Excluding criteria: age b18 or N75 years old, normal coronary
artery, no statin therapy or intermittent taking statin for less than
4 weeks. Patients with previous acute coronary syndrome within
1 month, serious heart failure or arrhythmia, infectious disease within
1month, serious liver or renal dysfunction, autoimmune disease, malig-
nant disease, pregnancy or lactation, or a psychiatric disorder were also
excluded from the study. CADwas deﬁned as at least onemain coronary
artery stenosis ≥70% by coronary angiography. Hypertension was de-
ﬁned as BP ≥ 140/90 mmHg or taking anti-hypertensive medicines. Di-
abetes mellitus was deﬁned as fasting glucose ≥7.0 mmol/L, random
glucose ≥11.1 mmol/L, or OGTT 2 h glucose ≥11.1 mmol/L or taking
anti-hyperglycemia medicines.
2.2. Statin therapy classiﬁcation
Statins in Chinese market include simvastatin, atorvastatin,
rosuvastatin, pravastatin, ﬂuvastatin, pitavastatin and lovastatin
(XueZhiKang). Based on 2013 ACC/AHA guideline on the treatment of
cholesterol, we classiﬁed statin intensity: (1) high-intensity (atorvastatin
40–80mg, rosuvastatin 20–40mg); (2)moderate-intensity (atorvastatin
10–20mg, rosuvastatin 5–10mg, simvastatin 20–40mg, pravastatin 40–
80 mg, ﬂuvastatin 80 mg, pitavastatin 2–4 mg) and (3) low-intensity
(simvastatin 10 mg, pravastatin 10–20 mg, ﬂuvastatin 20–40 mg).
2.3. Blood lipid measurements
Blood samples were obtained from the cubital vein after an over-
night fasting. All samples were analyzed after thawing within the ﬁrst24 h of the hospital admission. The concentrations of serum TC, TG,
HDL-C and LDL-C were measured using an automatic biochemistry
analyzer (Hitachi 7150, Tokyo, Japan) [7]. LDL-C was calculated
using the Friedewald equation [(TC-TG)/2.2], unless TG were elevated
(N4.5 mmol/L). Based on the guideline of 2010ESC/EAS cholesterol
management, the target of LDL-C level was deﬁned as b1.8 mmol/L for
very-high risk patients including patients with CAD [8].2.4. Statistical analyses
Data are presented as mean± SD,medianwith interquartile ranges,
or frequencieswith percentages, as appropriate.We used the chi-square
test to assess whether proportions were statistically signiﬁcant. The
level of signiﬁcance was established a priori at 2-sided p b 0.05. All
patients provided informed consent and each enrolling center obtained
institutional review board approval. All analyses were performed using
Statistical analysis was performed with SPSS version 19.0 software
(SPSS Inc., Chicago, Illinois, USA).3. Results
3.1. General characteristics of the patients before and after the announce-
ment of 2013 ACC/AHA guideline
The patients in group A were elder than in group B (58.24 ± 10.07
vs. 57.48 ± 9.82 years old, p b 0.05), the percentage of male patients
was higher in group A (76.2% vs. 73.1%, p b 0.05), the percentage of dys-
lipidemia was higher in group A (79.2% vs. 74.8%, p b 0.05). The level of
alanine transaminase(ALT), total bilirubin (TBIL) and direct
bilirubin(DBIL) was no signiﬁcantly different in both groups, except
the level of aspartate aminotransferase (AST) in group A was higher
than that in group B (22.37 ± 14.95 IU/L vs. 20.43 ± 14.05 IU/L,
p b 0.05). The level of glucose was higher in group A than in group B
(5.80± 1.72mmol/L vs. 5.67± 1.62mmol/L, p b 0.05). The level of cre-
atinine was higher in group A than that in group B (79.20 ±
20.32 μmol/L vs. 75.34 ± 17.83 μmol/L, p b 0.05), the level of high-
sensitive C-reactive protein (hs-CRP) was lower in group A than that
in group B(2.38 ± 2.98 mg/L vs. 2.66 ± 3.24 mg/L, p b 0.05). The level
of lipoprotein(a) [Lp(a)] was higher in group A than that in group B
(68.35 ± 23.64 mg/L vs. 65.89 ± 21.87 mg/L, p b 0.05) and the average
level of TC was lower in group A (3.84 ± 1.10 vs. 3.88 ± 1.09 mmol/L,
p b 0.05). Therewas no signiﬁcant difference in percentage of hyperten-
sion, current smoking and the average level of LDL-C between group A
and group B (Table 1).3.2. Comparison of constituent proportion of different kinds of statins
applications in both groups
Importantly, we found that the constituent ratio of different kinds
of statins application was signiﬁcantly different between the two
groups (p b 0.05), and the proportion of rosuvastatin application
grew up in group B (20.00%) when compared with group A
(10.50%, p b 0.05), the proportion of atorvastatin application kept
stable and maintained the most majority in two groups (53.60% in
group A, 51.10% in group B, Fig. 1)3.3. Comparison of average dosage of statins applications in both groups
However, we found that the mean dosage of atorvastatin (18.56 ±
5.06 mg vs.18.69 ± 6.55 mg) or rosuvastatin (10.34 ± 2.72 mg vs.
10.68 ± 4.06 mg) had no signiﬁcant change between the two groups
(Fig. 2).
Table 1
Comparison of baseline characteristics and lipid proﬁled in both groups (before and after
the announcement of 2013 ACC/AHA guideline).
Group A (n = 1521) Group B (n = 2071) p value
Age, years old 58.24 ± 10.07 57.48 ± 9.82 0.0225⁎
Male (%) 1160 (76.2) 1517 (73.1%) 0.0397⁎
Hypertension (n, %) 973 (64.3) 1321 (63.7%) 0.7380
Dyslipidemia (n, %) 1199 (79.2) 1550 (74.8%) 0.0018⁎
DM (n, %) 417 (27.6) 569 (27.4%) 0.9308
Current smoking (n, %) 865 (56.9) 1137 (54.8%) 0.2193
OMI (n,%) 517 (34.1%) 598 (29.8%) 0.0066⁎
ALT (IU/L) 31.93 ± 28.82 30.78 ± 25.50 0.2093
AST (IU/L) 22.37 ± 14.95 20.43 ± 14.05 0.0001⁎
TBIL (μmol/L) 15.08 ± 6.56 15.60 ± 6.05 0.3406
DBIL (μmol/L) 4.71 ± 2.02 3.10 ± 3.30 0.0396⁎
GLU (mmol/L) 5.80 ± 1.72 5.67 ± 1.62 0.0172⁎
Cr (μmol/L) 79.20 ± 20.32 75.34 ± 17.83 0.0000⁎
BUN (mmol/L) 5.54 ± 1.58 5.88 ± 1.66 0.0000⁎
HsCRP (mg/L) 2.38 ± 2.98 2.66 ± 3.24 0.0074⁎
Lp(a) (mg/L) 68.35 ± 23.64 65.89 ± 21.87 0.0013⁎
TC (mmol/L) 3.84 ± 1.10 3.88 ± 1.09 0.0031⁎
TG (mmol/L) 1.73 ± 1.00 1.74 ± 1.19 0.7140
HDL-C (mmol/L) 1.05 ± 0.27 1.02 ± 0.28 0.0067⁎
LDL-C (mmol/L) 2.32 ± 0.84 2.35 ± 0.96 0.2769
LDL-C b 1.8 mml/L, n (%) 422 (27.9%) 550 (26.9%) 0.5077
Notes: DM, diabetes mellitus, OMI, oldmyocardial infarction, SBP, systolic blood pressure,
DBP, diastolic blood pressure, HR, heart rate, GLU, glucose, Cr, creatinine, HsCRP, high-sen-
sitivity C-reactive protein, Lp(a), lipoprotein(a), TC, total cholesterol; TG, triglyceride;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
⁎ Means p b 0.05.
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Fig. 2. Comparison of average dosage (mg) of different statins used in groups before and
after the announcement of 2013 ACC/AHA guideline.
35N.-Q. Wu et al. / IJC Metabolic & Endocrine 14 (2017) 33–373.4. Comparison of the situation of different intensity statins applications in
both groups
The percentage of high-intensity statins was higher in group B than
groupA (2.9% in group B vs. 1.2% in groupA, p b 0.05) andhigh-intensity
statins still account for a very low rate in statins application even after
the announcement of 2013 ACC/AHA guideline. Moderate-intensity
statins account for the most part in statins application in both groups
(Fig. 3).26.50%
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Fig. 1. Comparison of constitution ratio of different statins used in groups before and after
the announcement of 2013 ACC/AHA guideline.3.5. Comparison of target achievement of LDL-C level in both groups
Unfortunately, it was found that the average LDL-C level in
each group was higher than 1.8 mmol/L (2.32 ± 0.84 mmol/Lin
group A vs. 2.35 ± 0.96 mmol/L in group B), the control rate of LDL-C
(LDL-C b 1.8 mmol/L) in both groups was still very low, and no
changewas found about the situation of LDL-C level target achievement
(b1.8 mmol/L) after the announcement of 2013 ACC/AHA guideline
(27.9% in group A vs. 26.9% in group B, p = 0.5077, Table 2)
3.6. Comparison of constitution proportion of different statins in the
subgroups with LDL-C level target achievement (b1.8 mmol/L) before and
after the announcement of 2013 ACC/AHA guideline
In both subgroups (subgroupA, n=422; subgroup B, n=550)with
LDL-C level target achievement (b1.8 mmol/L), baseline characteristics
including age, gender, percentage of hypertension or dyslipidemia or
DM, and the levels of ALT, AST, TBIL, DBIL, GLU, Cr, BUN, hs-CRP, Lp(a),
TC, TG, HDL-C and LDL-C were compared as shown in Table 2. The con-
stitution proportion of different statins after the announcement of 2013
ACC/AHA guideline had signiﬁcant differencewhen comparedwith that
before the announcement of 2013 ACC/AHA guideline. In details, the
proportion of rosuvastatin application was higher than before (28.5%
vs. 14.2%, p b 0.05, Fig. 4)
4. Discussion
The National Heart, Lung, and Blood Institute (NHLBI), in collabora-
tion with the American College of Cardiology (ACC) and the American1.20%
89.00%
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Fig. 3. Comparison of high-intensity, moderate-intensity and low-intensity statins
application in in groups before and after the announcement of 2013 ACC/AHA guideline.
Table 2
General characteristics in both subgroups with target achievement of LDL-C level
(b1.8 mmol/L) before and after the announcement of 2013 ACC/AHA guideline.
Subgroup A
(n = 422)
Subgroup B
(n = 550)
p value
Age, years old 58.20 ± 10.41 58.40 ± 9.73 0.7583
Male (%) 337 (80.0%) 426 (77.5%) 0.3280
Hypertension (n, %) 274 (65.4%) 346 (62.9%) 0.4244
Dyslipidemia (n, %) 328 (78.5%) 389 (70.9%) 0.0071⁎
DM (n, %) 126 (30.1%) 174 (31.6%) 0.6186
Current smoking (n, %) 242 (57.5%) 308 (56.0%) 0.6441
OMI (n, %) 308 (56.0%) 166 (30.7%) 0.9008
ALT (IU/L) 30.75 ± 30.70 28.93 ± 21.24 0.2982
AST (IU/L) 20.41 ± 15.43 20.75 ± 8.61 0.6867
TBIL (μmol/L) 15.77 ± 5.60 14.92 ± 5.68 0.3813
DBIL (μmol/L) 4.06 ± 6.44 3.53 ± 5.92 0.6077
GLU (mmol/L) 5.65 ± 1.63 5.64 ± 1.50 0.9131
Cr (μmol/L) 76.11 ± 16.56 79.76 ± 22.22 0.0035⁎
BUN (mmol/L) 5.79 ± 1.84 5.49 ± 1.56 0.0085⁎
HsCRP (mg/L) 2.46 ± 3.24 2.05 ± 2.78 0.0375
Lp(a) (mg/L) 63.24 ± 17.45 65.95 ± 19.31 0.0224⁎
TC (mmol/L) 3.02 ± 0.51 2.97 ± 0.62 0.2586
TG (mmol/L) 1.62 ± 1.24 1.61 ± 1.32 0.8914
HDL-C (mmol/L) 0.99 ± 0.27 0.97 ± 0.28 0.4249
LDL-C (mmol/L) 1.45 ± 0.26 1.44 ± 0.27 0.6686
Notes: DM, diabetes mellitus, OMI, oldmyocardial infarction, SBP, systolic blood pressure,
DBP, diastolic blood pressure, HR, heart rate, GLU, glucose, Cr, creatinine, HsCRP, high-sen-
sitivity C-reactive protein, Lp(a), lipoprotein(a), TC, total cholesterol; TG, triglyceride;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
⁎ Means p b 0.05.
36 N.-Q. Wu et al. / IJC Metabolic & Endocrine 14 (2017) 33–37Heart Association (AHA), released the revised cholesterol management
guideline in 2013 [6]. Themajor changes in the 2013ACC/AHAguideline
have created controversy and confusion among the medical commu-
nity, with some clinicians hesitant to embrace the shift. In some studies
to assess the impact of 2013 ACC/AHA guideline on the prescription
habit of statins of physicians, they mainly focused on the range of the
populations who should take statins (including primary and secondary
prevention) became wider after the announcement of the guideline,
and at the same time, they also were interested in the situation of
usage of high-intensity statins on the patients with ASCVD [9–13]. Our
study was a cross-sectional survey in order to investigate the situation
of statins prescriptions for those patientswith CAD inChina after the an-
nouncement of the 2013 ACC/AHA cholesterol management guideline.20.10%
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Fig. 4. Comparison of constitution proportion of different statins in the subgroups with
LDL-C level achievement (b1.8 mmol/L) before and after the announcement of 2013
ACC/AHA guideline.Different kinds of statins including high-intensity, moderate-intensity
and low-intensity statins were all available in the pharmacies of the
ﬁve hospitals. The present study data suggested that after the
announcement of 2013 ACC/AHA guideline, the usage of rosuvastatin
became more, however, with no signiﬁcant increase in dosage. The
proportion of high-intensity statins application was increasing after
the recommendation from the 2013 ACC/AHA guideline (2.9% vs. 1.2%,
p b 0.05), but was still very low. Not surprisingly, no improvement in
the proportion of target achievement of LDL-C level happened. Atorva-
statin was still the most commonly prescribed for the patients with
CAD, accounting for more than 50%. The prescription of rosuvastatin
was increasing after the announcement of 2013 ACC/AHA guideline,
suggesting that the cardiologists in China agreedwith the recommenda-
tion of “high-intensity statin should be used in those patientswith CAD”
in some extent.
We previously reported a multiple-center data from China in 2011
[14], less than 70% and 40% of Chinese patients with CAD achieve the
minimal LDL-C goal of b100 mg/dL and 70 mg/dL respectively, and
more than 10% of patients had an elevated level of TG or decreased
levels of HDL-C despite therapy. In DYSIS study published in 2014,
Zhao et al. reported that low rate of target achievement of LDL-C in
China [15], this cross-sectional trial included 25,697 patients treated
with lipid-lowering agents from 122 centers between April 2012 and
October 2012. Overall, 29.1% of patients had no lipid abnormalities,
and 38.5% of patients did not achieve the therapeutic goal for LDL-C,
either as a single lipid anomaly or associated with low HDL-C, elevated
TG, or both. Subjects with low risk were more likely than those with
very high and high risk to be at target LDL-C levels. Furthermore,
10.4% of very high-risk patients and 11.1% of high-risk patients who
attained the LDL-C goal failed to attain non-HDL-C goals.
Our study showed that even after 2013 ACC/AHA guideline
announcement, the rate of target achievement of LDL-C level in patients
with CADwas still very low. The situation as mentioned above in China
was not satisfying when comparing with that in western countries. In
the study performed in United States recently, Tran NJ et al. [16],
estimated the impact of the 2013 guideline on the pharmacy utilization
of cholesterol-loweringmedications in various risk groups in amanaged
care setting, they found that there would be a 25% increase in the pro-
portion of the overall population that is treated with statins over the
next 3 years, increasing from 3,909,407 (27.7%) patients to 4,892,668
(34.7%) patients. The largest proportion of the increase in statin utiliza-
tion was projected to be for primary prevention in patients aged 40 to
75 years who were not receiving any cholesterol-lowering treatment
at baseline. These projected changeswould increase the overall number
of statin prescriptions by 25% and will decrease the number of non-
statin cholesterol-lowering medication prescriptions by 68% during
the next 3 years. In addition, among the prospective cohort study of
consecutive patients hospitalized for acute coronary syndrome (ACS)
from 2009 to 2012 at four Swiss university hospitals [17], Gencer B
et al. analyzed 1602 patients who survived one year after recruitment,
1578 (99%) patients were prescribed statin at discharge, with 1120
(70%) at high-intensity. 1507 patients (94%) reported taking statin at
one year, with 909 (57%) at high-intensity. Among 482 patients
discharged with sub-maximal statin, intensiﬁcation of statin was only
observed in 109 patients (23%). 773 (47%) patients reached the
previous LDL-C targets, while 1014 (63%) reached the 2013 ACC/AHA
guideline targets one year after ACS (p value b 0.001).
In our study, the dosage of statins used in those patients with CAD
was compared before and after the announcement of 2013 ACC/AHA
guideline. In this study, the average dosage of atorvastatin and
rosuvastatin did not increase after the announcement of the guideline,
neither atorvastatin nor rosuvastatin achieved the dosage of the recom-
mendation in the guideline as high-intensity statins (atorvastatin
40-80 mg/day, rosuvastatin 20–40 mg/day). The average dosage
changes of different statins before and after the announcement of the
guideline were also compared in our study. The results showed that
37N.-Q. Wu et al. / IJC Metabolic & Endocrine 14 (2017) 33–37among the low and moderate-intensity statins, the dosage of simva-
statin became lower than before, while the dosages of other statins
including pravastatin, pitavastatin and lovastatin (Xuezhikang) had no
signiﬁcant change after the announcement of the guideline. The dosage
of ﬂuvastatinwas increasing due to the slow-releasing formulationwith
80 mg per tablet replacing 40 mg per capsule as fast-releasing
formulation.
As reported in our study, very low percentage (2.9%) of high-
intensity statins were used in those patients with CAD even the recom-
mendation of 2013 ACC/AHA guideline, suggesting that the cardiolo-
gists in the ﬁve hospitals were reluctant to prescribe high-intensity
statins for very high-risk patients. Similarly, in the survey of
Singapore, Sajita Setia et al. evaluated the impact of 2013 ACC/AHA
guideline on the usage of statins in Asian countries, they found that al-
though embracing the 2013 ACC/AHA guideline in clinical practice
was expected to provide better clinical care to patients, high reluctance
by physicians, especially in the use of high-dose statins [18]. Possible
reasons for the reluctance of high-intensity statins usage were listed
as following, the ﬁrst one was that doctors and patients worried about
potential side-effects of high-intensity statins, the second one was that
some patients could not afford the fees of long-term high-intensity
statins because no medical insurance covered in these patients, the
third one was that some ethnic difference in the baseline level of LDL-
C and response to statins between Asian and western populations. In
HPS2-THRIVE study, the rate of myopathy induced by statins in Chinese
patientswas about ten times than that in Europeanpatients [19]. Hence,
more relative study is needed for this dilemma of cholesterol control in
real world clinical practice.
There are some limitations in this study. Firstly, the sample size was
not large enough. Secondly, the general characteristics between both
the groups should be more matched to minimize the confounding
factors. Thirdly, the study feature of cross-section with several center
may not reﬂecting the whole situation in China with respect to the
cholesterol management including statin use and LDL-C target achieve-
ment. A survey of large sample sizewithmore centersmay be needed in
the future.
In summary, no much change of clinical practice with regard to
cholesterol management was found in Chinese patients with CAD,
accompanied by very low achievement of LDL-C target, suggesting
that there is a great room for the improvement of cholesterol control
in Chinese patients with CAD.
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